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INTRODUCTION
Prion diseases are a heterogeneous group of fatal neurodegenerative conditions characterized by the accumulation of abnormal forms of the cellular prion protein (PrP C ), termed PrP Sc , in the central nervous system (1) . The human prion diseases include idiopathic, genetically determined, and acquired forms of Creutzfeldt-Jakob disease (CJD), fatal familial insomnia, Gerstmann-Sträussler-Scheinker disease (GSS), and prion protein amyloid angiopathy. GSS is an autosomal dominant inherited neurodegenerative disorder associated with point mutations in the prion protein gene (PRNP), including P102L, P105L, A117V, G131V, H187R, F198S, D202N, Q212P, Q217R, and M232T. Furthermore, a GSS-like phenotype has been associated with 6Y9 extra octapeptide repeat insertional mutations in PRNP. GSS is characterized clinically by motor disorders and dementia and pathologically by deposition of PrP amyloid made up of N-and C-terminal truncated PrP fragments of 7 to 11 kDa in central nervous system (2, 3) . The clinical, pathologic, and biochemical features are variable among different GSS genotypes, but a phenotypic heterogeneity also exists both within and between families with the same mutation (3) . The 14-3-3 proteins, so named for their migration position on 2-dimensional di-ethyl-amino-ethyl chromatography and starch gel electrophoresis, belong to a family of highly conserved multifunctional polypeptides that are diffusely expressed in eukaryotic cells and are abundant in brain tissue, where they are preferentially localized in neurons and, at a lower level, in glial cells. Seven 14-3-3 isoforms (named F, A, T, R, ?, X, and G, from their reversed-phase highperformance liquid chromatography elution profile) with a high degree of sequence homology have been identified (4) . They are characterized by a molecular mass of approximately 30 kDa (33 kDa for the ? isoform) and assemble into homo-and heterodimeric complexes, which may interact with other proteins; these interactions are probably modulated by phosphorylation of the 14-3-3 binding partners (4, 5) . The 14-3-3 proteins are involved in a variety of biologic events, such as cell cycle control, apoptosis, and signaling pathway modulation (4, 6, 7) . A diagnostic value for 14-3-3 has been advanced after the observation that the protein is not detectable in the cerebrospinal fluid (CSF) of normal individuals, whereas it is increased in patients with rapidly progressing neurologic diseases associated with destruction of nerve tissue (8, 9) , particularly in Creutzfeldt-Jakob disease (CJD) (10) , in which selective detection of the F, A, ?, and G isoforms has been reported. At present, it is not known whether this is merely the consequence of rapid neuronal cell death or is related to a more specific involvement of the 14-3-3 proteins in prion diseases (11) .
Recently, the immunolocalization of the 14-3-3 ? protein has been found in PrP amyloid deposits of sporadic CJD and variant CJD, whereas no immunostaining was detected in amyloid plaques of Gerstmann-Sträussler-Scheinker disease (GSS) with P102L, A117V, and D202N mutations in the PRNP gene, nor in senile plaques of Alzheimer disease (AD) (12) . Moreover, the presence of 14-3-3 has been demonstrated in neurofibrillary tangles of AD (13) and in glial cytoplasmic inclusions of multiple system atrophy (MSA) (14) , suggesting that 14-3-3 proteins may play a role in the pathogenic mechanisms of these disorders. To verify the hypothesis of an involvement of 14-3-3 isoforms in the formation of PrP amyloid deposits, we carried out an immunohistochemical study and Western blot analysis of brain tissue samples from patients with GSS, familial, sporadic, and variant CJD, AD, and other neurodegenerative disorders, using antibodies specific for the all isoforms of 14-3-3 protein.
MATERIALS AND METHODS

Patients
We analyzed 9 patients with sporadic CJD, 5 patients with familial CJD (E200K = 2 and V210I = 3), 1 patient with variant CJD, 12 patients with GSS (F198S = 4, A117V = 3, P102L = 3, and Q217R = 2), 10 patients with AD, and 10 patients with other neurodegenerative disorders, including 2 cases of MSA, 2 cases of progressive supranuclear palsy, and 6 cases of frontotemporal dementia (4 sporadic and 2 with P301L mutation in the tau gene). The diagnosis and selection of the different forms of prion disease were based on neuropathologic examination, typing of PrP Sc by immunoblotting, and analysis of the PRNP gene, as previously described (15 
Histologic Analysis and Immunohistochemical Study
Brain samples, including different areas of the cerebral cortex and cerebellum, were fixed in Carnoy's solution (ethanol-chloroform-acetic acid, 6:3:1 v/v) or in 4% formaldehyde, dehydrated, and embedded in paraplast. Sections (10-Km-thick) were stained with hematoxylin and eosin and thioflavine S or probed with the monoclonal antibody 3F4 to residues 109 to 112 of human PrP at 1:5000 dilution (DakoCytomation, Glostrup, Denmark).
To determine the cerebral distribution of 14-3-3, we performed immunohistochemistry with a panel of antibodies recognizing the individual 14-3-3 isoforms and an antibody reactive with all isoforms (Santa Cruz Biotechnology, Santa Cruz, CA). Additional antibodies specific for the ? isoform of 14-3-3 (1 monoclonal antibody from Zymed, San Francisco, CA, and 1 polyclonal antibody from IBL, Gunma, Japan) were used for the immunohistochemical study. The characteristics of the anti-14-3-3 antibodies used are summarized in the Table. The tissue sections were processed for antigen retrieval by microwave heating in citrate buffer at pH 6. The slides were then incubated with the primary antibody (1:100, room temperature overnight), washed in Tris-buffered saline buffer, pH 7.5, incubated with the relevant biotinylated secondary antibody (1:200, room temperature, 1 hour; Vector Laboratories, Burlingame, CA) followed by streptavidin peroxidase (1:300, room temperature, 1 hour; Vector) and then developed in 3-3 ¶-diaminobenzidine (DakoCytomation). Controls sections were processed following the same procedure except for skipping the exposure to the primary antibody. Moreover, to test the specificity of the immunolabeling, sections were probed with the anti-14-3-3 antibodies previously incubated with the corresponding peptides (Santa Cruz Biotechnology). To verify the colocalization of 14-3-3 immunoreactivity with amyloid deposits, some sections immunostained for 14-3-3 were also treated with thioflavine S and analyzed by light and fluorescence microscopy. Other sections were immunostained with antibodies to glial fibrillary acidic protein, ubiquitin, and synaptophysin (DakoCytomation).
Immunohistochemistry on Semithin Sections and Immunoelectron Microscopy
Samples of cerebral and cerebellar cortex of a patient with GSS F198S were dissected from formalin-fixed tissue, washed in 0.4 mmol/L phosphate buffer, pH 7.4, containing 8% glucose for 7 days, postfixed in 2% glutaraldehyde overnight, dehydrated in acetone, and embedded in epoxy resin (Spurr; Electron Microscopy Sciences, Fort Washington, PA). Semithin sections were collected on l-polylisinate glass slides and dried at 60-C. The slides were immersed in an oversaturated solution of sodium methoxide overnight, washed in methanol, rehydrated in ethanol, treated with 98% formic acid for 20 minutes, rinsed in water, and incubated with 3% H 2 O 2 for 20 minutes followed by 5% normal goat serum for 30 minutes. The sections were then incubated with the antibodies to the ? and X isoforms of 14-3-3 (1:100 in Tris-HCl buffer, pH 7.5, room temperature, overnight), followed by EnVision + System-HRPYlabeled polymer antirabbit antibody (DakoCytomation) for 1 hour at room temperature. The reaction was visualized using 3,3 ¶-diaminobenzidine as a chromogen.
For immunoelectron microscopy, ultra-thin sections were placed on 200-mesh Formvar-carbonYcoated nickel grids (Electron Microscopy Sciences), etched in 1% sodium periodate for 60 minutes and treated with 60% formic acid for 3 minutes and 1% H 2 O 2 for 15 minutes. Residual aldehyde groups were quenched with 0.05 mmol/L glycine in PBS containing 5% bovine serum albumin for 30 minutes followed by anti-14-3-3 antibodies (1:50) in incubation buffer overnight at 4-C. After washing in PBS, grids were incubated for 3 hours with 10-nm gold-conjugated goat anti-rabbit secondary antibody (Aurion, Wageningen, the Netherlands) diluted 1:20. Grids were postfixed in 2% glutaraldehyde and 1% OsO 4 , counterstained with uranile acetate and lead citrate and observed with an EM109 electron microscope (Zeiss, Jena, Germany).
Western Blot Analysis
Frozen samples of cerebral cortex and cerebellum from patients with GSS (2 with F198S, 1 with A117V, 1 with Q217R, and 1 with P102L), 9 patients with sporadic CJD, 2 patients with AD, and 3 subjects with other neurodegenerative diseases were homogenized in 9 volumes of cold lysis buffer (100 mmol/L NaCl, 10 mmol/L EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 10 mmol/L Tris, pH 7.4) and the protein concentration was determined by bicinchonic acid assay (Pierce Chemical, Rockford, IL). Sample aliquots equivalent to 50 Kg of protein were fractionated on 12.5% sodium dodecyl sulfateYpolyacrylamide minigels under Quantitative analysis of 14-3-3 bands was performed by densitometry as described previously (15) .
RESULTS
Histologic Analysis and Immunohistochemistry
The immunohistochemical study showed that 14-3-3 is widely distributed in the central nervous system of normal individuals. The protein is mainly localized in neurons but is also present in glial cells and diffusely in the neuropil with a finely granular pattern according to previous published data (17, 18) . Some differences were apparent in the distribution and degree of expression of specific 14-3-3 isoforms. A gradient of expression was found with the 14-3-3 X being the most expressed, whereas ?, 5, A, G, F, and R were expressed in decreasing order. Moreover, the 14-3-3 ? antibody decorated the astrocytes better than the antibodies to the other isoforms. This pattern was substantially identical in control subjects and patients with prion diseases and the other neurodegenerative condition examined. However, a generalized decrease of immunostaining for all the 14-3-3 isoforms was observed in the CJD cases, compared with the FIGURE 2. In Gerstmann-Sträussler-Scheinker disease (GSS), 14-3-3 ? isoform immunoreactivity colocalizes with thioflavine S fluorescence in prion protein (PrP) amyloid deposits. In cored plaques (A, B) the immunolabeling is more intense at the periphery of amyloid deposits (arrow), whereas diffuse ones (arrowheads) are uniformly decorated (C, D). A section of the cerebellum of a GSS F198S was incubated with the 14-3-3 ? antibody revealed by DAB as chromogen (brown reaction product) (A, C) and then treated with thioflavine S (B, D). The same amyloid deposits that exhibit yellow fluorescence after thioflavine S are detectable by 14-3-3 ? immunohistochemistry. The antibody to the ? isoform decorated the PrP amyloid plaques of all GSS patients, although the intensity of immunostaining was generally stronger in F198S individuals than in patients with the P102L, A117V, or Q217R mutation. The pattern of immunoreactivity was characterized by diffuse staining of amyloid associated with intense labeling of small, round profiles within the plaques, particularly at the periphery (Fig. 1) . The immunolabeling of PrP amyloid plaques for the ? isoform of 14-3-3 in the different GSS cases was consistent using 3 different antibodies (polyclonal from Santa Cruz, polyclonal from IBL, and monoclonal from Zymed) and corresponded to the different types of PrP deposits found in GSS, i.e. amyloid cores, multicentric plaques, and diffuse plaques. Counterstaining with thioflavine S revealed that virtually all amyloid deposits in GSS brains were labeled by the anti 14-3-3 ? antibody (Fig. 2) . By contrast, immunostaining with antibodies against the other 14-3-3 isotypes was absent in amyloid plaques of GSS, suggesting a nonsignificant involvement of isoforms other than ? in the composition of GSS amyloid deposits (Fig. 1D) . We also examined the immunoreactivity of GSS plaques for ubiquitin and synaptophysin, which was strong in cellular profiles at the periphery of the amyloid deposits (data not shown), partially overlapping the punctuate immunostaining for 14-3-3 ?.
In sporadic CJD, only the antibody against the 14-3-3 ? isoform elicited a faint immunostaining of Kuru plaques in patients heterozygous at codon 129 of PRNP, whereas all 14-3-3 antibodies, including the anti-14-3-3 ?, failed to detect the other types of PrP deposits. Senile plaques of AD did not show immunoreactivity with any of the antisera against the 14-3-3 isoforms (Fig. 3) , whereas both the neurofibrillary tangles of AD and the neuronal tau immunoreactive inclusions of frontotemporal dementia as well as the glial inclusions of MSA were labeled by all the 14-3-3 antibodies (data not shown). No immunostaining was observed in sections probed with anti-14-3-3 antibodies previously incubated with the corresponding peptides in patients with prion diseases and other degenerative conditions and in control subjects.
Ultrastructural Analysis and Immunoelectron Microscopy
In semithin sections of cerebral and cerebellar cortex from a GSS F198S patient, uni-and multicentric amyloid plaques were strongly labeled by the anti-14-3-3 ? antibody, whereas immunostaining for the X isoform was absent. Ultrastructural examination showed that the plaques were formed by 8-to 10-nm-thick, straight, unbranched fibrils with variable orientation, intermingled with small, round magnification (12,000Â) of the plaque shows that the amyloid fibrils are immunodecorated by the anti-14-3-3 ? antibody (10-nm gold particles). There is also a significant diffuse interfibrillar immunoreactivity for the anti-14-3-3 ? antibody. Scale bars = 0.6 Km.
osmiophilic structures. With immunoelectron microscopy using the anti-14-3-3 ? antibody, gold particles were detected along and around fibrils (Fig. 4) . On the contrary, we did not detect any immunolabeling within the GSS plaques with the anti-14-3-3 X antibody.
Western Blot Analysis
The analysis of brain homogenates from control subjects and patients with GSS, CJD, AD, and other neurodegenerative disorders showed a similar pattern of expression of 14-3-3 isoforms. The most intense band at the immunoblot was that corresponding to the X isoform followed by ?, 5, A, G, F, and R in decreasing order (Fig. 5) . If compared to the signal of the X isoform, the relative intensities of the ?, 5, A, G, F, and R bands, measured by densitometry, were 51%, 27%, 26%, 23%, 9%, and 0.4%, respectively. This pattern matched that found by immunohistochemistry and was identical in different regions, indicating a homogeneous distribution of 14-3-3 species in the human brain.
Western blot analysis of brain homogenates with the anti-14-3-3 ? antibody in GSS patients with different PRNP mutations and control subjects resulted in the same profile marked by a single 33-kDa band (Fig. 6 ).
DISCUSSION
The view that 14-3-3 could be relevant in the pathogenesis of prion diseases and other neurodegenerative conditions stems from the finding of a significant increase of this protein in the CSF of patients with Creutzfeldt-Jakob disease, along with the observation that 14-3-3 is involved in regulation of various fundamental proteins such as ion channels (19, 20) , modulators of cell cycling and apoptosis (21Y23), cytoskeleton-related proteins (e.g. dynein [24] ), signaling messengers (25, 26) , and enzymes (27) .
An active role of 14-3-3 in the pathogenesis of neurodegenerative diseases is supported by the detection of the protein in several pathologic inclusions that characterize these conditions, such as neurofibrillary tangles of AD (13) and glial cytoplasmic inclusions of MSA (14) . In our study the antibodies against all of the 14-3-3 isoforms immunolabeled neurofibrillary tangles, suggesting a nonspecific involvement of the various protein isotypes in the tau-associated pathologic changes in patients with AD and frontotemporal dementia as well as >-synucleinYrelated deposits in MSA cases, as previously reported (14, 28) . Nevertheless, only the ?, F, X, and 5 isotypes of 14-3-3 have been demonstrated in Lewy bodies of Parkinson disease (29, 30) , suggesting that distinct 14-3-3 species, which are encoded by separate genes, have a selective involvement in specific pathologic conditions.
With regard to prion diseases, it has been reported that the A, F, ?, and G isotypes in particular are present in the CSF of CJD patients (11) and that PrP amyloid deposits of variant and sporadic CJD contain the 14-3-3 X isoform but not the other isoforms (12) . Our findings could not confirm the results of this previous immunohistochemical study and show that the ? isoform is the only species consistently associated with PrP amyloid plaques of GSS patients, suggesting variation in the involvement of the 14-3-3 isotypes also among different prion diseases. Because the 14-3-3 ? isoform was not found in amyloid deposits of AD and CJD patients, this isoform may be related to a specific interaction with the PrP amyloid peptides of GSS rather than to unspecific binding to amyloid. Recently, evidence of binding between 14-3-3 and PrP has been provided by Satoh et al (31) , who showed that 14-3-3 forms a molecular complex with PrP C and the heat shock protein Hsp60. The close spatial relationship between the 14-3-3 ? and the PrP fibrils in GSS amyloid implies a possible contribution of this molecule to the aggregation of PrP. The modulation of PrP fibrillogenesis may be related to the ability of 14-3-3 in promoting the interfacing between different molecules, putting them into the correct mutual position (4) . Because all the other 14-3-3 isoforms are absent in the GSS amyloid, this effect points to a specific molecular affinity between 14-3-3 ? and the abnormal PrP isoforms or the small size PrP amyloid peptides of GSS (i.e. 7Y8 kDa size) (2, 32, 33) . Furthermore, it is possible to hypothesize that the GSS-associated PRNP mutations could specifically facilitate the interaction between the ? isoform of 14-3-3 and the PrP conformers incorporated into the amyloid plaques, because such an interaction apparently does not take place in PrP deposits of sporadic, variant, and familial CJD. However, it cannot be excluded that the 14-3-3 ? interferes with the fibrillogenesis in PrP amyloid of GSS, as suggested by the previously described ability of 14-3-3 in preventing protein aggregation in vitro (34) .
It is noteworthy that the diffuse, finely granular immunolabeling of 14-3-3 ? was reminiscent of the pattern of immunoreactivity obtained with antibodies against synaptic markers as synaptophysin. This is in accordance with previous studies indicating that the ? isoform of 14-3-3 is located in the synapses at the level of vesicles and plasma membranes, where it is anchored through its N-terminal 
region (4). In addition, PrP
C is abundant at the synaptic plasma membrane (35) and this colocalization could favor the interaction between the 2 molecules.
Finally, the results obtained by Western blot analysis on the brain regional distribution of the 14-3-3 proteins showed no significant differences between prion diseases and other neurodegenerative diseases. A decreased signal was observed for all the 14-3-3 isoforms in cases characterized by more prominent neurodegeneration. It is conceivable that this was the consequence of the massive neuronal loss that is likely to be the cause of leakage of 14-3-3 in the extracellular space and can be related to its detection in the CSF of CJD patients.
In summary, immunohistochemical data suggest the accumulation of specific isoforms of 14-3-3 in different kinds of PrP-related deposits, which could be due to an active role of 14-3-3 isotypes in the pathogenesis of prion diseases, most likely with a role as a chaperone of the ? isoform in GSS. Further studies are necessary to assess whether the colocalization of the 14-3-3 ? isoform and PrP in amyloid in GSS reflects a favoring or inhibiting effect on PrP fibrillogenesis and to define the function of the 14-3-3 ? isoform in the formation of PrP-amyloid deposits in GSS.
